为解决肝癌患者对乐伐替尼（Lenvatinib）响应率低和易产生耐药性的问题，研究人员开展了肝癌中乐伐替尼耐药机制及联合治疗的研究。结果发现 PDGFRA 过表达介导耐药，阿伐替尼（Avapritinib）可增强乐伐替尼疗效。这为肝癌治疗提供新策略。

We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe.

CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025 ...

The American Academy of Arts and Sciences was founded in 1780 by John Adams, John Hancock and a group of other American leaders to promote research and learning. Since then, elected members have ...